StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The firm has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- Best Aerospace Stocks Investing
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Upcoming IPO Stock Lockup Period, Explained
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Invest in Small Cap StocksĀ
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.